Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CHEK-ATP154 | Human | HEK293/Human STEAP1 Stable Cell Line | |||
| ST1-H5283 | Human | Human STEAP1 Full Length Protein, Twin-Strep,His Tag (Detergent) |  |
|
|
| SCCHO-ATP121 | Human | CHO/Human STEAP1 Stable Cell Line Development Service |
Fig. FACS analysis of STEAP1 on HEK293/Human STEAP1 Stable Cell Line.
FACS assay shows that Anti-STEAP1 antibody can bind to HEK293/Human STEAP1 Stable Cell Line. HEK293/Human STEAP1 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).
Expression analysis of human STEAP1 on CHO/Human STEAP1 Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human STEAP1 Stable Cell Line or negative control cell using anti-human STEAP1 antibody followed by staining with PE anti-human IgG Fc Antibody.
Human STEAP1 Full Length Protein, Twin-Strep,His Tag (Cat. No. ST1-H5283) captured on CM5 chip via anti-His antibody can bind Anti-STEAP1 Antibody with an affinity constant of 3.43 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| 89Zr-DFO-MSTP2109A | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Genentech Inc | Prostatic Neoplasms | Details | |
| STEAP1 CART Cell Therapy(PromiCell) | Phase 2 Clinical | PromiCell Therapeutics Inc, Fred Hutchinson Cancer Research Center | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | |
| Xaluritamig | AMG-509 | Phase 1 Clinical | Xencor Inc, Amgen Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| ABBV-969 | ABBV-969; ABBV969 | Phase 1 Clinical | Abbvie Inc, Immunogen Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| 89Zr-DFO-MSTP2109A | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Genentech Inc | Prostatic Neoplasms | Details | |
| STEAP1 CART Cell Therapy(PromiCell) | Phase 2 Clinical | PromiCell Therapeutics Inc, Fred Hutchinson Cancer Research Center | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | |
| Xaluritamig | AMG-509 | Phase 1 Clinical | Xencor Inc, Amgen Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| ABBV-969 | ABBV-969; ABBV969 | Phase 1 Clinical | Abbvie Inc, Immunogen Inc | Prostatic Neoplasms, Castration-Resistant | Details |
This web search service is supported by Google Inc.
A-Z
